Pharmaceutical industry is a sunrise industry, especially the biopharmaceuticals, which just starts its large-scale industrialization process. Many large biotech and pharmaceutical companies are strengthening their presence worldwide. Compared with traditional pharmaceutical industry, biopharmaceutical industry sees a higher market concentration, and this is more helpful for strong enterprises to grow stronger and for building a number of leading enterprises in the segment areas. Currently, traditional chemical pharmaceutical makers also start turning their eyes towards biopharmaceutical field, and keep themselves busy in establishing much more strategic alliance.

China's pharmaceutical industry has been growing at 20% on the average in production value over the past decade, nearly doubled every four years. In Jan-Jul 2007, the accumulated production value of the entire industry reached RMB 342.449 billion, up 23.47% compared to the same period of last year, of which, production value of bio-pharmaceuticals was RMB 30.229 billion, up 24.37% from a year earlier.

Total Industrial Output Value and Growth, Jan-Jul 2007

 
 
Source: State Information Center

China's biopharmaceutical industry could not only produce internationally important biologic drugs, but develop independently new biological drugs. Furthermore, China has achieved great breakthrough in gene engineering, biopharmaceuticals and clone technology. Despite of the rapid growth, there are still serious problems in China's biopharmaceutical industry:

China is weak in the investment, R&D capability and technology innovation;
There are serious repeated construction problems in drug development and production;
Overall, enterprises are small-sized, and with low modernization level and outmoded equipments;
Marketing strategies are unreasonable, mainly in brand development;
Management is outdated and talents capable of both technology and operation fall short;
 There are no enough exchange and cooperation among enterprises.

Biopharmaceutical industry includes four segment markets: gene engineering, bacterin, blood products and diagnostic reagent. After more than a decade of development, these four segment markets find many aggressive private or state-owned biopharmaceutical enterprises through which China is to fulfill its supports to the whole industry. As far as capital market is concerned, as concept investment bubble fades away, Chinese pharmaceutical enterprises are expected to be gradually accepted by the market with its high growth potentials.

Polices have a great influence on China's biopharmaceutical industry, so how many efforts China will make to support the industry plays a significant role in its development. In fact, China always keeps a close eye on biopharmaceutical industry and has frequently issued related policies in recent two years, which is very positive for stimulating the development of biopharmaceutical industry and for regulating industry rules, and also brings energy and opportunities into the biopharmaceutical industry.

Related Laws and Regulations Issued in 2007

Based on the study on China pharmaceutical industry's status quo, competitive pattern, investment and developing trend, this report puts its emphasis on output and sales situation of main drugs, impact China's pharmaceutical industry will face as well as strategies enterprises should make.

2 Overview of Biopharmaceutical Industry
2.1 Brief introduction to biopharmaceutical industry
2.1.1 Definition
2.1.2 Development history
2.2 Main products and characteristics of biopharmaceutical industry
2.2.1 Main products
2.2.2 Characteristics
2.3 Development status of global pharmaceutical industry
2.3.1 USA
2.3.2 Europe
2.3.3 Japan
2.3.4 India

3 Environments in China Biopharmaceutical Industry
3.1 Macro environments
3.1.1 General situation of macroeconomic in China, 2007
3.1.2 Economic operations of China pharmaceutical industry
3.1.3 Influences caused by variational macro environments in China medical treatment field
3.2 Policy environments
3.2.1 Drug registration
3.2.2 Drug production
3.3.3 Drug circulation
3.3.4 Drug application
3.2.5 Supervision on sub-industries

4 Status Quo of China Biopharmaceutical Industry
4.1 Operations
4.2 Production technology
4.3 Major problems
4.3.1 Enterprises operate mostly at a small size
4.3.2 Repeated construction problems are serious
4.3.3 R&D capability is weak
4.3.4 Industry concentration is at a low level
4.3.5 Basic R&D results are unable to be converted efficiently

5 Industrial Systems in China Biopharmaceutical Industry
5.1 Biopharmaceutical industry systems
5.2 Problems exist in China biopharmaceutical industry systems
5.3 Value chain analysis in biopharmaceutical industry

6 Main biopharmaceutical products
6.1 Blood products
6.1.1 Operations status
6.1.2 Main blood products
6.1.3 Competitiveness
6.2 Bacterin
6.2.1 Overview of Bacterin market
6.2.2 Polices on immunity plan promote bacterin market to grow fast
6.2.3 Market competitiveness
6.2.4 Segment markets

7 Listed Companies
7.1 Hualan Biological Engineering Inc.
7.1.1 Company Profile
7.1.2 Operations in 2007
7.1.3 Opportunities and risks
7.2 Shanghai Kehua Bio-engineering Co., Ltd
7.2.1 Company profile
7.2.2 Operations in 2007
7.2.3 Risks
7.3 Beijing Tiantan Biological Products Co., Ltd
7.3.1 Company profile
7.3.2 Operations in 2007
7.3.3 Opportunities and risks
7.4 Da An Gene Co., Ltd of Sun Yat-Sen University
7.4.1 Company profile
7.4.2 Operations in 2007
7.4.3 Opportunities and risks

8 Foreign Companies in China
8.1 Bayer
8.1.1 Operations in China
8.1.2 Investments in China
8.2 AstraZeneca
8.3 Pfizer
8.3.1 Operations in China
8.3.2 Investments in China
8.4 Sanofipasteur
8.5 Novartis
8.6 GlaxoSmithKline (GSK)
8.7 Lilly
8.8 Co-operative Group